“Bronchodilator combinations for COPD: real hopes or a new Pandora's box?” Nicolas Roche and Pascal Chanez. Eur Respir J 2013; 42: 1441–1445.


Source: Eur Respir J 2014; 43: 658
Journal Issue: February
Disease area: Airway diseases

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
“Bronchodilator combinations for COPD: real hopes or a new Pandora's box?” Nicolas Roche and Pascal Chanez. Eur Respir J 2013; 42: 1441–1445.. Eur Respir J 2014; 43: 658

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
“Towards a total ban on links with the tobacco industry: new rules for the ERS.” Klaus F. Rabe, Christina Gratziou, Brian Ward and Florence Berteletti. Eur Respir J 2012; 40: 809–810.
Source: Eur Respir J 2012; 40: 1307
Year: 2012


“Dead space: the physiology of wasted ventilation.” H. Thomas Robertson. Eur Respir J 2015; 45: 1704–1716.
Source: Eur Respir J 2015; 46: 1226
Year: 2015


“Exercise pulmonary haemodynamics: a test in search of purpose.” J. Gerry Coghlan and Harm Jan Bogaard. Eur Respir J 2016; 47: 1315–1317.
Source: Eur Respir J 2016; 48: 285
Year: 2016


“Lung cancer survival in Norway, 1997–2011: from nihilism to optimism.” Yngvar Nilssen, Trond Eirik Strand, Lars Fjellbirkeland, Kristian Bartnes and Bjørn Møller. Eur Respir J 2016; 47: 275–287.
Source: Eur Respir J 2016; 47: 1297
Year: 2016


“Lung function race, ethnicity: a conundrum.” Philip H. Quanjer. Eur Respir J 2013; 41: 1249–1251.
Source: Eur Respir J 2013; 42: 1162
Year: 2013


“Alveolar macrophages carbon load: a marker of exposure?” Chinedu Nwokoro, Rossa Brugha and Jonathan Grigg. Eur Respir J 2013; 41: 763.
Source: Eur Respir J 2013; 42: 295
Year: 2013


“Do bacteria have a role in asthma development?” J. Armann and E. von Mutius. Eur Respir J 2010; 36: 469–471.
Source: Eur Respir J, 54 (1) 1050414; 10.1183/13993003.50414-2010
Year: 2019


“GINA 2015: the latest iteration of a magnificent journey.” Jean Bousquet and Marc Humbert. Eur Respir J 2015; 46: 579–582.
Source: Eur Respir J 2015; 46: 1854
Year: 2015


“Cardiovascular disease and COPD: dangerous liaisons?” Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev 2018; 27: 180057.
Source: Eur Respir Rev, 27 (150) 185057; 10.1183/16000617.5057-2018
Year: 2018


“Number needed to treat: enigmatic results for exacerbations in COPD.” Samy Suissa. Eur Respir J 2015; 45: 875–878.
Source: Eur Respir J, 51 (6) 1452165; 10.1183/13993003.52165-2014
Year: 2018


“Long-term volume-targeted pressure-controlled ventilation: sense or nonsense?” Maria Paola Arellano-Maric, Cesare Gregoretti, Marieke Duiverman and Wolfram Windisch. Eur Respir J 2017; 49: 1602193.
Source: Eur Respir J, 50 (1) 1652193; 10.1183/13993003.52193-2016
Year: 2017


“Electronic nicotine delivery systems (ENDS): the beginning of the end or the end of the beginning?” Francesco Blasi and Brian Ward. Eur Respir J 2014; 44: 585–588.
Source: Eur Respir J 2015; 45: 861
Year: 2015


“Is bronchiectasis really a disease?” Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051.
Source: Eur Respir Rev, 29 (155) 195051; 10.1183/16000617.5051-2019
Year: 2020


“Adult-onset asthma: is it really different?” Selma B. de Nijs, Lisette N. Venekamp and Elisabeth H. Bel. Eur Respir Rev 2013; 22: 44–52.
Source: Eur Respir Rev 2013; 22: 193
Year: 2013


“RESPIRE: breathing new life into bronchiectasis.” Sanjay H. Chotirmall and James D. Chalmers. Eur Respir J 2018; 51: 1702444.
Source: Eur Respir J, 51 (2) 1752444; 10.1183/13993003.52444-2017
Year: 2018


“Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD.” Ciro Casanova and Bartolome R. Celli. Eur Respir J 2014; 43: 951–953.
Source: Eur Respir J 2014; 43: 1825
Year: 2014


“The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment.” Silvia Ulrich and Ekkehard Grunig. Eur Respir J 2021; 57: 2004376
Source: Eur Respir J, 57 (3) 2054376; 10.1183/13993003.54376-2020
Year: 2021


“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.
Source: Eur Respir Rev 2015; 24: 545
Year: 2015


“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021.
Source: Eur Respir Rev, 28 (153) 195021; 10.1183/16000617.5021-2019
Year: 2019


“Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options.” Winfried Randerath, Oana Deleanu, Sophia Schiza and Jean-Louis Pepin. Eur Respir Rev 2019; 28: 190084.
Source: Eur Respir Rev, 28 (154) 195084; 10.1183/16000617.5084-2019
Year: 2019